Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP: Looking at the current areas of development for biosimilars, you can utilize these in the up-front setting or relapsed-refractory setting. When that preference occurs is still an unknown area. I think that when we’re continuing therapy, we’ll probably continue these brand-name therapies based on continualization in the curative setting. Again, the key question here is curative. There will be a preference early on to continue with that brand-name biologic therapy. As time goes on, in a year or 2, we’ll see more and more uptake of the biosimilarization.
Even though the preference is there—by a physician team, by team members—the payers will actually define what we use, because we have to get prior authorization of biosimilars up front or biologics. Based on the current utilization or integration of what those policies are developed as, then in these cases—even though they may have a preference or they may say “I trust one biologic rather than the biosimilar”—we’ll see a payer define that early on. There’s a consistent communication based on the payer and institutions defining what that actual pathway is.
When the next step evolves, that will be a discussion on when to integrate that in the institution and also how familiar you feel with those drug therapies as well. That next step is part of that educational piece, which is truly a lack of integrating those biosimilars into the next-step pathway. When we start taking a look at biosimilar integration, over time, we’ll see more familiarity because of use and adverse-event profiles, which should be different, becoming a mainstay of those discussions. That familiarity will bring about increased utilization for physician and team members as well.
Kashyap Patel, MD: Biologics and biosimilars—let me go back to biologics first. Biologics have really revolutionized the treatment of cancer patients. Until 15 years back, all we had were some highly toxic chemotherapy that was almost, like, the bomb that you would use in a large dose and then hope that the cancer tissue dies and the normal tissue recovers.
The biologics target the specific cell, getting a specific marker on the surface. Biologics have revolutionized the management of cancer patients. But they’re really expensive, and the biosimilars have allowed us to replace expensive biologic drugs with relatively less expensive ones—not a whole lot of difference, maybe 15%, 20%, 30% less, but any savings to the system is savings. That’s why biosimilars have been very promising for continuing the accessibility and affordability for cancer patients in our country.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings
February 28th 2024A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.